Bradley Hickey,Nimfa Teneza-Mora,Joanne Lumsden,Sharina Reyes,Martha Sedegah,Lindsey Garver,Michael R. Hollingdale,Jo Glenna Banania,Harini Ganeshan,Megan Dowler,Anatalio Reyes,Cindy Tamminga,Alexandra Singer,Alicia Simmons,Maria Belmonte,Arnel Belmonte,Jun Huang,Sandra Inoue,Rachel Velasco,Steve Abot,Carlos S. Vasquez,Ivelese Guzman,Mimi Wong,Patrick Twomey,Mariusz Wojnarski,James Moon,Yolanda Alcorta,Santina Maiolatesi,Michele Spring,Silas Davidson,Sidhartha Chaudhury,Eileen Villasante,Thomas L. Richie,Judith E. Epstein

Abstract:BACKGROUND: Immunization with radiation-attenuated sporozoites (RAS) by mosquito bite provides >90% sterile protection against Plasmodium falciparum (Pf) malaria in humans. RAS invade hepatocytes but do not replicate. CD8+ T cells recognizing parasite-derived peptides on the surface of infected hepatocytes are likely the primary protective mechanism. We conducted a randomized clinical trial of RAS immunization to assess safety, to achieve 50% vaccine efficacy (VE) against controlled human malaria infection (CHMI), and to generate reagents from protected and non-protected subjects for future identification of protective immune mechanisms and antigens.METHODS: Two cohorts (Cohort 1 and Cohort 2) of healthy, malaria-naïve, non-pregnant adults age 18-50 received five monthly immunizations with infected (true-immunized, n = 21) or non-infected (mock-immunized, n = 5) mosquito bites and underwent homologous CHMI at 3 weeks. Immunization parameters were selected for 50% protection based on prior clinical data. Leukapheresis was done to collect plasma and peripheral blood mononuclear cells.RESULTS: Adverse event rates were similar in true- and mock-immunized subjects. Two true- and two mock-immunized subjects developed large local reactions likely caused by mosquito salivary gland antigens. In Cohort 1, 11 subjects received 810-1235 infected bites; 6/11 (55%) were protected against CHMI vs. 0/3 mock-immunized and 0/6 infectivity controls (VE 55%). In Cohort 2, 10 subjects received 839-1131 infected bites with a higher first dose and a reduced fifth dose; 9/10 (90%) were protected vs. 0/2 mock-immunized and 0/6 controls (VE 90%). Three/3 (100%) protected subjects administered three booster immunizations were protected against repeat CHMI vs. 0/6 controls (VE 100%). Cohort 2 uniquely showed a significant rise in IFN-γ responses after the third and fifth immunizations and higher antibody responses to CSP.CONCLUSIONS: PfRAS were generally safe and well tolerated. Cohort 2 had a higher first dose, reduced final dose, higher antibody responses to CSP and significant rise of IFN-γ responses after the third and fifth immunizations. Whether any of these factors contributed to increased protection in Cohort 2 requires further investigation. A cryobank of sera and cells from protected and non-protected individuals was generated for future immunological studies and antigen discovery.TRIAL REGISTRATION: ClinicalTrials.gov NCT01994525.

Recombinant full-length Plasmodium falciparum circumsporozoite protein-based vaccine adjuvanted with GLA-LSQ: Results of Phase 1 testing with malaria challenge

Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria.

First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naïve adults

Safety and Efficacy of a Monoclonal Antibody Against Malaria in Mali.

PfSPZ-CVac malaria vaccine demonstrates safety among malaria-experienced adults: A randomized, controlled phase 1 trial

Robust antibody and CD8+ T-cell responses induced by P. falciparum CSP adsorbed to cationic liposomal adjuvant CAF09 confer sterilizing immunity against experimental rodent malaria infection

Sporozoite immunization: Innovative Translational Science to Support the Fight against malaria

IMRAS—A clinical trial of mosquito-bite immunization with live, radiation-attenuated P. falciparum sporozoites: Impact of immunization parameters on protective efficacy and generation of a repository of immunologic reagents

Probing novel epitopes on the Plasmodium falciparum circumsporozoite protein for vaccine development

A Pfs48/45-based vaccine to block Plasmodium falciparum transmission: phase 1, open-label, clinical trial

IMRAS-Immunization with Radiation-Attenuated Plasmodium Falciparum Sporozoites by Mosquito Bite: Cellular Immunity to Sporozoites, CSP, AMA1, TRAP and CelTOS

Design and Evaluation of Chimeric Plasmodium falciparum Circumsporozoite Protein-Based Malaria Vaccines

Subclass and avidity of circumsporozoite protein specific antibodies associate with protection status against malaria infection

Mapping of safe and early chemo-attenuated live Plasmodium falciparum immunization identifies immune signature of vaccine efficacy

Whole sporozoite immunization with Plasmodium falciparum strain NF135 in a randomized trial

A candidate antibody drug for prevention of malaria

mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum

Clinical formulation development of Plasmodium falciparum malaria vaccine candidates based on Pfs48/45, Pfs230, and PfCSP

Malaria vaccine candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a Phase I trial

Establishing RTS,S/AS01 as a benchmark for comparison to next-generation malaria vaccines in a mouse model

Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity